KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) EBIT: 2011-2024

Historic EBIT for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to -$323.8 million.

  • Travere Therapeutics' EBIT rose 144.40% to $24.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$91.1 million, marking a year-over-year increase of 74.50%. This contributed to the annual value of -$323.8 million for FY2024, which is 16.57% up from last year.
  • According to the latest figures from FY2024, Travere Therapeutics' EBIT is -$323.8 million, which was up 16.57% from -$388.1 million recorded in FY2023.
  • Travere Therapeutics' 5-year EBIT high stood at -$176.2 million for FY2020, and its period low was -$388.1 million during FY2023.
  • Moreover, its 3-year median value for EBIT was -$323.8 million (2024), whereas its average is -$343.9 million.
  • As far as peak fluctuations go, Travere Therapeutics' EBIT plummeted by 60.37% in 2022, and later increased by 16.57% in 2024.
  • Over the past 5 years, Travere Therapeutics' EBIT (Yearly) stood at -$176.2 million in 2020, then fell by 13.20% to -$199.4 million in 2021, then tumbled by 60.37% to -$319.8 million in 2022, then fell by 21.36% to -$388.1 million in 2023, then grew by 16.57% to -$323.8 million in 2024.